There were documented critical situations of peliosis hepatis, often associated with liver failure and intra-abdominal hemorrhage; liver tumors, in some cases deadly; and blood lipid variations connected to amplified possibility of atherosclerosis led FDA to eliminate approval in June 2023. More warnings incorporate the hazards linked to cholestatic hepatitis, hypercalcemia https://equipoise34567.blogacep.com/40521085/the-definitive-guide-to-tren